Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study

Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits PD-L1:PD-1 and PD-L1:B7.1 interactions, restoring anticancer immunity. Here, we report final analyses from the non-small-cell lung cancer (NSCLC) cohort of the first atezolizumab phase I study. Patients with NSCLC received at...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2018-09, Vol.101, p.201-209
Hauptverfasser:	Horn, Leora, Gettinger, Scott N., Gordon, Michael S., Herbst, Roy S., Gandhi, Leena, Felip, Enriqueta, Sequist, Lecia V., Spigel, David R., Antonia, Scott J., Balmanoukian, Ani, Cassier, Philippe A., Liu, Bo, Kowanetz, Marcin, O'Hear, Carol, Fassò, Marcella, Grossman, William, Sandler, Alan, Soria, Jean-Charles
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Anticancer properties Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Apoptosis Appetite loss Atezolizumab B7 antigen B7-H1 Antigen - biosynthesis Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Confidence intervals Dyspnea Fatigue Fatigue - chemically induced Female Humans Hyponatremia Hypoxia Immune checkpoint inhibitor Immune system Immunity Immunohistochemistry Immunotherapy Kaplan-Meier Estimate Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Male Medical treatment Metastases Middle Aged Monoclonal antibodies Nausea Nausea - chemically induced Neoplasm Metastasis Non-small cell lung carcinoma Non-small-cell lung cancer Patients PD-1 protein PD-L1 PD-L1 protein Respiration Safety Subgroups Survival Targeted cancer therapy Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!